Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) has a beta value of 0.02 and has seen 1.79 million shares traded in the last trading session. The company, currently valued at $1.98B, closed the last trade at $7.85 per share which meant it gained $0.08 on the day or 1.03% during that session. The MRVI stock price is -47.26% off its 52-week high price of $11.56 and 42.42% above the 52-week low of $4.52. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.46 million shares traded. The 3-month trading volume is 1.94 million shares.
The consensus among analysts is that Maravai LifeSciences Holdings Inc (MRVI) is Buy stock at the moment, with a recommendation rating of 1.60. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 7 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.01.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) trade information
Sporting 1.03% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the MRVI stock price touched $7.85 or saw a rise of 1.01%. Year-to-date, Maravai LifeSciences Holdings Inc shares have moved 19.85%, while the 5-day performance has seen it change 10.41%. Over the past 30 days, the shares of Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) have changed 0.26%. Short interest in the company has seen 8.97 million shares shorted with days to cover at 6.69.
Wall Street analysts have a consensus price target for the stock at $22, which means that the shares’ value could jump 64.32% from current levels. The projected low price target is $10.0 while the price target rests at a high of $25.0. In that case, then, we find that the current price level is -218.47% off the targeted high while a plunge would see the stock gain -27.39% from current levels.
Maravai LifeSciences Holdings Inc (MRVI) estimates and forecasts
Figures show that Maravai LifeSciences Holdings Inc shares have underperformed across the wider relevant industry. The company’s shares have lost -12.39% over the past 6 months, with this year growth rate of -166.67%, compared to 11.60% for the industry. Revenue growth from the last financial year stood is estimated to be -4.60%.
12 analysts offering their estimates for the company have set an average revenue estimate of 67.55M for the current quarter. 12 have an estimated revenue figure of 70.46M for the next ending quarter. Year-ago sales stood 66.86M and 74.14M respectively for this quarter and the next, and analysts expect sales will grow by 1.00% for the current quarter and -4.60% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -37.53% over the past 5 years. Earnings growth for 2024 is a modest -211.42% while over the next 5 years, the company’s earnings are expected to increase by 61.34%.
MRVI Dividends
Maravai LifeSciences Holdings Inc is expected to release its next earnings report on 2024-Nov-07 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI)’s Major holders
Insiders own 1.36% of the company shares, while shares held by institutions stand at 103.96% with a share float percentage of 105.39%. Investors are also buoyed by the number of investors in a company, with Maravai LifeSciences Holdings Inc having a total of 301.0 institutions that hold shares in the company. The top two institutional holders are GTCR LLC with over 20.15 million shares worth more than $144.27 million. As of 2024-06-30, GTCR LLC held 15.2267% of shares outstanding.
The other major institutional holder is 12 WEST CAPITAL MANAGEMENT LP, with the holding of over 13.21 million shares as of 2024-06-30. The firm’s total holdings are worth over $94.59 million and represent 9.9833% of shares outstanding.
